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Abstract 
Background: In malaria endemic populations, complex patterns of Plasmodium vivax and Plasmodium falciparum 
blood-stage infection dynamics may be observed. Genotyping samples from longitudinal cohort studies for merozo-
ite surface protein (msp) variants increases the information available in the data, allowing multiple infecting parasite 
clones in a single individual to be identified. msp genotyped samples from two longitudinal cohorts in Papua New 
Guinea (PNG) and Thailand were analysed using a statistical model where the times of acquisition and clearance of 
each clone in every individual were estimated using a process of data augmentation.
Results: For the populations analysed, the duration of blood-stage P. falciparum infection was estimated as 36 (95% 
Credible Interval (CrI): 29, 44) days in PNG, and 135 (95% CrI 94, 191) days in Thailand. Experiments on simulated data 
indicated that it was not possible to accurately estimate the duration of blood-stage P. vivax infections due to the  
lack of identifiability between a single blood-stage infection and multiple, sequential blood-stage infections caused 
by relapses. Despite this limitation, the method and data point towards short duration of blood-stage P. vivax infec-
tion with a lower bound of 24 days in PNG, and 29 days in Thailand. On an individual level, P. vivax recurrences cannot 
be definitively classified into re-infections, recrudescences or relapses, but a probabilistic relapse phenotype can be 
assigned to each P. vivax sample, allowing investigation of the association between epidemiological covariates and 
the incidence of relapses.
Conclusion: The statistical model developed here provides a useful new tool for in-depth analysis of malaria data 
from longitudinal cohort studies, and future application to data sets with multi-locus genotyping will allow more 
detailed investigation of infection dynamics.
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Background
Plasmodium falciparum and Plasmodium vivax malaria 
parasites cause persistent blood-stage infections in 
humans lasting for weeks, months, and occasionally 
years [1]. The processes of parasite growth (as asex-
ual merozoites invade red blood cells and periodically 
replicate every 48 h), density-dependent regulation, and 
the acquisition of adaptive immune responses cause 
complex patterns of blood-stage parasitaemia and 
infection dynamics [2–5]. In addition to blood-stage 
parasite replication, P. vivax has an alternative strategy 
for persisting in humans via the reservoir of hypnozo-
ites in the liver [6]. Following inoculation of P. vivax 
sporozoites from an infectious mosquito, a propor-
tion of sporozoites will develop into hypnozoites and 
remain arrested in the liver for weeks to years [7, 8], 
until they activate to cause new blood-stage infections. 
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Blood-stage infections arising from the activation of P. 
vivax hypnozoites are referred to as relapses, and are 
a key distinguishing feature between the biology of P. 
vivax and P. falciparum [9].
A recurrent infection is defined as a newly detectable 
episode of blood-stage parasitaemia occurring after a 
previous infection [7]. A P. falciparum recurrence can be 
due to: (i) re-infection from a new mosquito bite; or (ii) 
recrudescence, where blood-stage parasites originating 
from a previous infection persist at sub-patent densities 
where the probability of detection is low, before increas-
ing in density to become detectable. A P. vivax recur-
rence can be due to: (i) re-infection; (ii) recrudescence; or 
(iii) relapse. It is usually not possible to definitively dis-
tinguish between types of recurrences without detailed 
genotyping information. Re-infections can be excluded if 
an individual has moved to an area with no malaria trans-
mission [10]. Relapses can be excluded if individuals are 
treated with an effective regimen of primaquine [11]—
the only licensed drug capable of eliminating hypnozoites 
from the liver [12]. However, even with directly observed 
treatment, primaquine does not guarantee clearance 
of hypnozoites in human patients with a low CYP2D6 
metabolizer phenotype [13]. Recrudescences can be 
excluded with high-sensitivity testing for blood-stage 
parasites, for example if prior to a positive blood sample 
an individual tested negative by qPCR, then it’s unlikely 
that the positive sample was due to a recrudescence.
Qualitative and quantitative descriptions of P. falcipa-
rum and P. vivax infection dynamics have been obtained 
through analysis of data from historic malaria-therapy 
studies used for the treatment of neuro-syphilis [14, 15]. 
In these highly controlled studies, exposure to infec-
tious mosquito bites was strictly regulated and blood-
stage parasite densities measured frequently, often daily, 
allowing for detailed investigation of temporal patterns 
in blood-stage parasite densities [2]. A number of limi-
tations prevent the findings of these studies from being 
extrapolated to malaria-endemic regions, notably that 
subjects were malaria-naïve adults without pre-existing 
immunity, and the absence of super-infection with new 
strains.
In contemporary times, the dynamics of malaria infec-
tions may be studied in endemic regions using longitudi-
nal cohort studies, where participants are followed over 
time and sampled frequently [16, 17].
Participants will have varying degrees of naturally-
acquired immunity and may be concurrently exposed to 
both P. vivax and P. falciparum infections. Genotyping 
of Plasmodium parasites increases the information avail-
able from samples, allowing for super-infections to be 
identified, and multiplicity of infection to be estimated 
[18, 19]. These data can be analysed using statistical 
and mathematical models to estimate epidemiological 
parameters of interest. The dynamics of genotyped P. fal-
ciparum infections from longitudinal studies have previ-
ously been analysed using triplet or immigration-death 
models [20, 21], where the frequencies of different pat-
terns of samples are analysed to provide estimates of the 
duration of blood-stage infection; the detectability of 
genotypes; and the force of infection of each genotype. A 
limitation of these methods is the assumption that dura-
tion of infection is exponentially distributed. In an analy-
sis of P. falciparum samples from a longitudinal study in 
Ghana, Bretscher et  al. [22] overcame this limitation by 
fitting a range of distributions to the duration of blood-
stage infection, but at the expense of assuming re-infec-
tion with the same genotype is a rare event. Accounting 
for the role of P. vivax relapses in longitudinal studies 
remains a considerable challenge. Using data on time to 
relapse from malaria-therapy studies and keeping dura-
tion of blood-stage infection constant, Ross et  al. [17] 
fitted a population-level model to data from a cohort of 
Papua New Guinean children, and estimated that 80% of 
P. vivax infections were attributable to relapses.
In this analysis, infection dynamics were estimated by 
estimating the times of acquisition and clearance of P. 
falciparum and P. vivax single-locus genotypes in each 
individual. Data from infections in all individuals were 
analysed simultaneously allowing estimation of the aver-
age duration of blood-stage infection, the probability of 
genotype detectability, and for P. vivax: the duration of 
liver-stage infection with hypnozoites and relapse fre-
quency. Although a definitive classification of P. vivax 
infections into re-infection, recrudescence or relapse 
is not possible, it was possible to assign a probabilistic 
phenotype to each positive P. vivax sample, facilitating 
detailed investigation of the role of relapses in epidemio-
logical studies.
Methods
Longitudinal cohort data
Maprik, Papua New Guinea
Between 2009 and 2010, 529 children aged 5–10  years 
were recruited in Maprik District, East Sepik Province, 
Papua New Guinea where both P. falciparum and P. 
vivax are hyperendemic [23]. Full details of the study are 
provided in Robinson et  al. [11]. In brief, after screen-
ing for G6PD deficiency, 504 children were randomized 
to receive 20 days of directly observed treatment (DOT) 
over 4 weeks of either: (i) chloroquine (CQ) (DOTs 1–3), 
artemether-lumefantrine (AL) (DOTs 11–13), and pri-
maquine (PQ) (DOTs 1–20; 0.5 mg/kg); or (ii) CQ (DOTs 
1–3), AL (DOTs 11–13), and placebo (PL) (DOTs 1–20). 
The high dose of primaquine in arm (i) ensured effec-
tive elimination of hypnozoites from the liver. Children 
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were followed longitudinally with active monitoring for 
infection by PCR and illness every 2  weeks for the first 
12  weeks. From weeks 14–32 children were actively 
monitored for illness every 2  weeks and blood-samples 
for PCR were collected every 4  weeks. Active monitor-
ing was supplemented via passive surveillance for symp-
tomatic episodes through local health centres and aid 
posts. Clinical malaria infections (i.e. fever and parasitae-
mia confirmed by rapid diagnostic test) were treated with 
AL, thus hypnozoites were not eliminated during follow-
up in both arms. An overview of the data is provided in 
Table 1.
Kanchanaburi and Ratchaburi, Thailand
Between 2013 and 2014, 999 participants aged 
1–82 years were recruited in Kanchanaburi and Ratch-
aburi provinces of western Thailand, where moder-
ate levels of P. vivax transmission and low levels of P. 
falciparum are reported. This cohort had substantially 
lower levels of P. vivax and P. falciparum infection 
than the Papua New Guinean cohort. Full details of the 
study are provided in Longley et al. [24]. In this obser-
vational cohort study, participants were not treated 
upon recruitment and were followed longitudinally for 
12 months, with blood samples collected every month 
(14 active case detection visits in total). Active moni-
toring was supplemented by samples recruited through 
passive case detection where participants with temper-
ature ≥ 37.5 °C or with a history of fever were checked 
for malaria using a rapid diagnostic test (RDT). RDT 
positive individuals were referred to local health clinics 
where Thai malaria treatment guidelines applied: chlo-
roquine and primaquine for P. vivax and artemisinin-
based combination therapy (ACT) for P. falciparum. All 
samples were assessed by qPCR for the presence of P. 
falciparum or P. vivax parasites. qPCR positive samples 
were then genotyped. An overview of the data is pre-
sented in Table 1.
Simulated data
Simulated data sets on the dynamics of P. falciparum 
and P. vivax genotypes in longitudinal studies were gen-
erated across a range of parameter values for the dura-
tion of blood-stage infection, genotype detectability 
and time to relapse. Details are provided in Additional 
file  3. The simulated data sets were assumed to have 
demography matching the Papua New Guinean cohort.
Laboratory methods and genotyping
Laboratory studies were undertaken in Basel for the 
Papua New Guinean samples and in Bangkok for the 
Thai samples, with external quality control undertaken 
in The Walter and Eliza Hall Institute in Melbourne (C 
Koepfli). Finger-prick blood samples collected during 
follow-up were separated into plasma and red cell pel-
lets and stored at − 80 and − 20 °C, respectively. DNA 
was extracted using the FavorPrep 96-Well Genomic 
DNA Extraction Kit (Favorgen, Taiwan) from the red 
cell pellet fraction of all samples. Plasmodium spp. 
Table 1 Overview of longitudinal cohort data from Papua New Guinea and Thailand
The data from PNG is for the period after the initial drug regimen. Missing data is defined as the proportion of samples scheduled in the study protocols missed. Data 
on age, numbers of genotypes detected during follow-up, and duration of follow-up are presented as mean and ranges. Light microscopy (LM) data was not available 
for the Thai samples
Papua New Guinea (n = 504) Thailand (n = 999)
Placebo arm (n = 257) Primaquine arm (n = 247)
Gender (male) 49.8% (128) 48.6% (120) 46.2% (462)
Age (years) 7.5 (4.9, 10.4) 7.6 (4.8, 10.4) 23 (1, 82)
Bednet usage 93.4% (240) 93.1% (230) 88.8% (888)
Duration of follow-up (days) 224 (56, 231) 224 (42, 229) 369 (360, 378)
Proportion of data missing 12.3% 10.1% 8.3%
Any P. vivax infection by qPCR 69.6% (179) 27.9% (69) 11.9% (119)
Any P. vivax infection by LM 54.5% (140) 21.9% (54) –
Number of P. vivax genotypes 2.2 (0, 12) 0.7 (0, 7) 0.3 (0, 11)
Any P. falciparum infection by qPCR 37.0% (95) 34.0% (84) 2.4% (24)
Any P. falciparum infection by LM 23.7% (61) 27.9% (69) –
Number of P. falciparum genotypes 0.6 (0, 9) 0.5 (0, 6) 0.03 (0, 6)
Any fever 53.7% (138) 62.3% (154) 24.7% (247)
Any fever with  qPCR+ P. vivax 10.1% (26) 4.0% (10) 2.1% (21)
Any fever with  qPCR+ P. falciparum 9.7% (25) 16.6% (41) 0.3% (3)
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infections were detected using a generic qPCR to detect 
all four species [25], after which species-specific (P. 
falciparum, P. vivax, Plasmodium malariae, and Plas-
modium ovale) qPCRs were performed on Plasmo-
dium-positive samples [26]. All PCRs were conducted 
on 4 µL DNA, corresponding to 4 µL blood. To deter-
mine the number of genetically distinct blood-stage 
clones in each sample, P. vivax and P. falciparum posi-
tive samples were genotyped. Size polymorphic molec-
ular markers were amplified by a nested PCR, followed 
by capillary electrophoresis for sizing. For P. vivax the 
marker msp1F3 [19] was typed, and for P. falciparum 
the marker msp2 [27]. These genotyping markers have 
expected heterozygosity in excess of 90%. The limit of 
detection of the molecular methods was 1–3 copy num-
bers/µL [28]. Some samples were qPCR positive for P. 
falciparum or P. vivax, but did not test positive for any 
genotype. These samples were assumed to be negative 
for all considered genotypes. For the present model the 
14 most common alleles were included. In Thailand 
they accounted for 88% of all P. falciparum and 76% of 
all P. vivax clones, and in PNG for 88% of all P. falcipa-
rum and 86% of all P. vivax clones.
Data overview
For the 504 individuals in the PNG cohort, and the 999 
individuals in the Thai cohort, a wide range patterns 
for the presence or absence of the P. falciparum and P. 
vivax genotypes were observed. Figure 1 shows a sum-
mary of these patterns in terms of the distribution of 
number of consecutive positive samples. The data pat-
terns are further summarized in Additional file 1.
Statistical inference
The data and model have a three level structure. (i) On 
the individual-level, data from each genotype in each 
participant provides information on the times of acqui-
sition and clearance of infections. (ii) The genotype-level 
combines data from all participants to provide informa-
tion on the genotype-specific force of infection. (iii) The 
population-level combines data from all participants 
and all genotypes to provide information on duration of 
Fig. 1 Distribution of number of consecutive positive samples for individuals infected with a P. falciparum in PNG; b P. falciparum in Thailand; c 
P. vivax in PNG; and d P. vivax in Thailand. The colours denote the frequency of the 14 most common genotypes. The grey region represents the 
frequency of the rest of the genotypes. The mean time between samples was 18 days in PNG, and 29 days in Thailand
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blood-stage and liver-stage infection, genotype detect-
ability, and relapse frequency. A mixed-effects framework 
allows for a synthesis of information across all levels. For 
example, if samples are missing from one individual the 
infection dynamics during the period of missed sampling 
will depend on the population-level parameters. Statisti-
cal inference was implemented in a Bayesian framework 
with parameters updated according to a Metropolis–
Hastings MCMC algorithm implemented in C++. Prior 
information on population-level parameters was 
assumed based on previously published studies (Table 2). 
Full details are provided in Additional file 2.
Model overview
Genotyping of malaria infections in longitudinal cohorts 
allows for multiple infections in the same individual 
originating from different mosquito bites to be distin-
guished from one another. The infection dynamics of a 
P. falciparum or P. vivax single-locus genotype within an 
individual can be represented schematically as shown in 
Fig. 2. Sample j measured at time point τ j can be either 
positive (xj= 1) or negative (xj= 0) for a given genotype. 
The sequence of positive and negative samples in Fig. 2 
could be due to two separate infections of the same gen-
otype, with the first infection acquired at T 1
inf
∈ (τ 1, τ 2) 
and clearing at T 1
clear
∈ (τ 3, τ 5) , and the second infection 
acquired at T 2
inf
∈ (τ 3, τ 5) and clearing at T 2
clear
∈ (τ 7, τ 8) . 
Alternatively, with a probability depending on the geno-
type detectability q, the four positive samples could be 
from a single infection that was not detected in the sam-
ples at τ 4 and τ 5 . Importantly, the acquisition and clear-
ance times are unknowable (the examples depicted in 
Fig. 2a are just one possible combination). Instead their 
distribution is estimated by treating them as parameters 
in a process of data augmentation.
Given P. falciparum genotype data in an individual, 
the likelihood that the samples are described by acqui-
sition times Tk
inf
 and clearance times Tk
clear
 can be calcu-
lated, where each separate infection is indexed by k. This 
requires us to assume values for the detectability q, the 
force of infection of that genotype λ, and a distribution 
for the duration of blood-stage infection of a single geno-
type (e.g., a Weibull distribution with mean dBS and shape 
parameter κWB) [22]. Notably, the duration of blood-stage 
infection dkBS = Tkclear − Tkinf will be limited to the period 
when it is detectable via molecular genotyping. The aug-
mented parameters Tk
inf
 and Tk
clear
 can then be updated 
using a Markov Chain Monte Carlo (MCMC) routine. 
Upon convergence, the MCMC chains will provide distri-
butions for Tk
inf
 and Tk
clear
.
When this method is applied to data from individual 
participants, knowledge of population-level parameters 
(q, λ, dBS, κWB) is required. However, these population-
level parameters are not necessarily known for a given 
transmission setting, so they are estimated simultane-
ously with the individual-level augmented parameters. 
Statistical inference is implemented in a multi-level 
framework, so that updating population-level parameters 
affects the likelihood for all individuals, and the aug-
mented infection time parameters are updated for one 
individual at a time. When patterns from multiple indi-
viduals and multiple genotypes are combined, informa-
tion on the infection dynamics on a population level can 
be obtained. For example, if there are many 00100 pat-
terns this would indicate short durations of blood-stage 
infection (or low detectability). If there are many 01110 
patterns this would indicate longer durations of blood-
stage infection and higher detectability.
The P. falciparum model allows for probabilistic dif-
ferentiation between re-infection (due to new mos-
quito bites) and recrudescence (due to a blood-stage 
Table 2 Population-level parameter estimates for the P. falciparum and P. vivax infection dynamics models fitted to data 
from PNG and Thailand
Notably, the estimates for blood-stage infection are for the duration when parasites are detectable by molecular genotyping. Prior parameter estimates are derived 
from the cited studies. Parameters are presented as estimated posterior medians with 95% credible intervals. The estimates for the P. vivax parameters should be 
interpreted in light of the results of the experiments on simulated data which indicated that it was not always possible to consistently and accurately estimate the 
duration of blood-stage infection and the time to relapse
Description Parameter Prior P. falciparum P. vivax
PNG Thailand PNG Thailand
Blood-stage duration (days) [4] dBS 60 (16, 132) 36 (29, 44) 135 (94, 191) 24 (21, 28) 29 (27, 32)
Shape parameter κ 2.0 (0.5, 4.4) 0.50 (0.45, 0.57) 1.15 (0.79, 1.78) 0.54 (0.49, 0.62) 0.40 (0.38,0.42)
Pf detectability [43] q 70%  (64%, 76%) 66% (60%, 71%) 67% (61%, 73%) – –
Pv detectability [43] q 48%  (42%, 54%) – – 44% (40%, 49%) 38% (35%, 41%)
Time to relapse (days) [7] 1/f 50 (19, 96) – – 41 (35, 49) 55 (40, 80)
Liver-stage duration (days) [30] 1/γL 250 (195, 312) – – 383 (313, 467) 226 (181, 278)
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sample that has previously gone undetected). In order 
to account for P. vivax relapses, population-level param-
eters describing the epidemiology of relapses need to 
be defined [29, 30]. Define f to be the relapse frequency. 
Relapses are assumed to occur at a constant rate so that 
the average time between primary attack and first relapse 
will be 1/f, the average time between first and second 
relapses will be 1/f, and so on as long as hypnozoites are 
present in the liver. Notably, a relapse can occur when 
blood-stage parasites from the primary infection are 
still circulating, but it will be impossible to detect if the 
parasites have the same genotype. Define γL to be the 
rate of clearance of liver-stage infection, such that the 
average time the liver spends infected with hypnozoites 
after an infectious bite is 1/γL. Given the population-level 
parameters describing the epidemiology of relapses (f and 
γL), it can be calculated that the likelihood that P. vivax 
genotype data from an individual is described by infec-
tion times Tk
inf
 and Tk
clear
 . Notably, each new infection 
can be due to either a re-infection or a relapse, but not a 
recrudescence which is considered to be persistence of a 
previous infection. The probability that a new infection is 
a relapse can be calculated and will depend on the relapse 
frequency f and the genotype-specific force of infection λ. 
Full details of the statistical methodology are provided in 
Additional file 2.
Results
Assessment of model performance with simulated datasets
The statistical methods were applied to simulated data 
sets with known values of the population-level param-
eters describing the infection dynamics of P. falcipa-
rum (dBS, κWB, q, λ) and P. vivax (dBS, κWB, q, f, γL, λ), to 
investigate whether it was possible to accurately estimate 
Fig. 2 Schematic of infection dynamics of a single genotype from an individual in a longitudinal cohort study. a Samples are collected at times 
τj, and are either negative (xj = 0) or positive (xj = 1). In this example the samples after the period of prophylaxis can be encoded as 01100110. 
Examples of possible times for the acquisition Tinf and clearance Tclear of two infections are shown. b The exact values of Tinf and Tclear are unknown 
and hence are treated as parameters whose distributions are estimated via data augmentation. The green region denotes the probability that the 
first infection is present at that time. The orange region denotes the probability that the second infection of the same genotype is present at that 
time
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these parameters (i.e. whether the method could repro-
duce these known parameter values). The full results 
are described in detail in Additional file  3. Data sets 
were simulated under assumptions of either: constant 
exposure to infectious mosquito bites; heterogeneity in 
exposure; or seasonality in exposure. Figure 3 shows the 
method’s performance for estimating the duration of 
blood-stage infection in simulated data. For P. falcipa-
rum dBS was accurately estimated across large regions of 
parameter space. However, there was a notable tendency 
to underestimate dBS when genotype detectability was 
low. Low genotype detectability leads to positive sam-
ples being missed, causing long sequences of consecu-
tive samples to be split into several shorter sequences. 
dBS was also underestimated for small values of κWB—the 
shape parameter of the Weibull distribution. Smaller val-
ues of κWB correspond to greater variation in the duration 
of blood-stage infection, leading to many short infections 
and fewer long infections.
For the simulated P. vivax data, dBS was consistently 
underestimated across all regions of parameter space. 
This leads to the conclusion that the method cannot relia-
bly estimate the duration of blood-stage P. vivax infection 
because of a lack of identifiability between a blood-stage 
infection of long duration following a mosquito bite or a 
blood-stage infection of short duration rapidly followed 
by relapses. However, the estimates of dBS can be viewed 
as a lower bound for the duration of blood-stage P. vivax 
infection. The underestimation of dBS was accompanied 
by underestimation of the time to next relapse (1/f)—see 
Additional file 3. This issue of lack of identifiability of the 
duration of blood-stage P. vivax infection arises from the 
inability of the method to distinguish between a blood-
stage infection with a single-locus genotype of long dura-
tion, and a blood-stage infection of short duration rapidly 
followed by relapses of the same genotype. The estimates 
of the duration of blood-stage P. vivax infections and the 
time to next relapse presented here should therefore be 
treated with caution.
Fig. 3 Results of model validation on simulated data. The x-axis shows the value for the duration of blood-stage infection (dBS) used to simulate 
the data, and the y-axis shows the estimated median and 95% credible intervals. Circles denote data simulated assuming no heterogeneity and 
seasonality of exposure to infectious mosquito bites. Triangles denote data simulated assuming heterogeneity in exposure. Squares denote data 
simulated assuming seasonality in exposure. Each panel represents a different combination of detectability (q) and shape parameter (κWB) for either 
P. falciparum or P. vivax 
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Single genotype infection dynamics
For each of the 14 most common P. falciparum and P. 
vivax genotypes in all individuals in the PNG and Thai 
cohorts, the blood-stage infection dynamics were esti-
mated. Figure  4 shows the infection dynamics of single 
P. falciparum and P. vivax genotypes in three individuals. 
For each positive sample, it is possible to read off from 
the figure the estimated probability that the detected 
parasites are from the first, second or third infection. 
In PNG participant 1, the three positive P. falciparum 
samples (Fig.  4a) are due to a single infection with 94% 
probability (i.e. a single infection spans the full duration 
of these samples), or two separate infections with 6% 
probability. The two positive P. vivax samples (Fig.  4b) 
are from the same infection with 8% probability or from 
separate infections with 92% probability. Each infection 
in Fig. 4b is due to either a re-infection or a relapse. Fig-
ure  4c shows these infections’ breakdown according to 
the probability of being a relapse or not. The first positive 
sample (70 days after the end of the primaquine course) 
is estimated to be a relapse with 17% probability. How-
ever the second positive sample at 168 days is a relapse 
with 74% probability. Figure 4d–f shows the results from 
an individual in the placebo arm of the PNG cohort. This 
individual received two AL treatments clearing blood-
stage infections. In particular, after first treatment, the 
P. vivax genotype will reappear very rapidly, with a high 
probability of it being a relapse (Fig.  4f ). Figure  4g–i 
shows the dynamics of a P. falciparum and P. vivax gen-
otype in an individual in the Thai cohort. P. falciparum 
Fig. 4 Probability of the presence of P. falciparum and P. vivax genotypes. a–c Infection dynamics in PNG participant 1. d–f Infection dynamics 
in PNG participant 2. g–i Infection dynamics in Thai participant 1. For each genotype within each individual, the colours denote whether that 
genotype is predicted to be present at a given time arose from that individual’s first, second or third infection. Each P. falciparum infection comes 
from a separate mosquito bite. Each P. vivax infection comes from either a new mosquito bite or a relapse. The bottom row depicts the probability 
that a new infection with a P. vivax genotype is due to re-infection from mosquito or relapse. The grey region denotes the period of prophylaxis 
when participants were treated with AL and chloroquine, and either primaquine or a placebo. During the period of follow-up AL treatment was 
administered by the investigators to some of the Papua New Guinean participants
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infection (of any genotype) was rare, and most partici-
pants in the Thai cohort remained free from infection. 
Figure  4 shows the infection dynamics for 2/504 Papua 
New Guinean participants and 1/999 Thai participants. 
The infection dynamics for an additional six participants 
are shown in Additional file 4.
Multiple genotype infection dynamics
For each individual the infection dynamics of each geno-
type can be combined to describe the diversity of infec-
tion. Figure  5 shows the infection dynamics for the 14 
most common genotypes for the same three individuals 
depicted in Fig.  4. What may appear to be single P. fal-
ciparum or P. vivax blood-stage infections when sam-
ples are tested with light microscopy or PCR, is often a 
complex series of infections. In particular, for PNG par-
ticipant 2 in the placebo arm where liver-stage hypnozo-
ites were not removed, a very high diversity of P. vivax 
infection was observed, even after blood-stage parasites 
are removed with AL treatment. In Thailand, where 
transmission intensity was much lower, fewer genotypes 
within each blood-stage infection were observed. The 
infection dynamics of multiple P. falciparum and P. vivax 
genotypes for an additional six individuals are shown in 
Additional file 4.
Population‑level infection dynamics
The infection dynamics for each genotype in each indi-
vidual can be aggregated to provide an overview of the 
infection dynamics on the population level. Figure  6 
shows estimated genotype prevalence in both cohorts. 
The estimated prevalence is systematically greater than 
the observed prevalence (Additional file 4: Fig. S4.5) due 
to imperfect genotype detection. The temporal variation 
in P. vivax genotype prevalence in Thailand (Fig.  6f ) is 
most likely due to seasonal variation in malaria transmis-
sion [24]—a pattern also seen for P. falciparum (Fig. 6e), 
albeit more weakly due to the small number of positive 
samples. In contrast, there is no clear seasonal pattern 
in P. falciparum genotype prevalence in PNG (Fig.  6a, 
c), despite previous observations of seasonal variation 
in exposure to infectious mosquito bites in the study 
region [23]. In the placebo arm of the PNG study, a nota-
ble peak in P. vivax genotype prevalence around day 70 
was observed (Fig. 6b). As a similar peak is not observed 
in P. vivax genotype prevalence in the primaquine arm 
(Fig.  6a), or of P. falciparum genotype prevalence in 
either arm (Fig. 6c, d), it is likely that the delayed peak in 
P. vivax following blood-stage treatment is due to a factor 
other than seasonality. This peak most likely arises from 
relapsing hypnozoites originating from mosquito bites 
before or during the period of prophylactic protection. 
However, if exposure to P. vivax infectious mosquitoes is 
assumed to be constant, then the incidence of relapses in 
a population is also expected to be constant, and hence a 
reduction in P. vivax geneotype prevalence after the peak 
at day 70 is not expected. The reduction in P. vivax preva-
lence following the peak at day 70 must, therefore, be due 
Fig. 5 Infection dynamics of multiple P. falciparum and P. vivax genotypes. a, b Infection dynamics in PNG participant 1. c, d Infection dynamics in 
PNG participant 2. e, f Infection dynamics in Thai participant 1. For both P. falciparum and P. vivax each genotype is represented by a different colour
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to some factor not explicitly accounted for in this model. 
Some plausible hypotheses for this pattern are: (i) the 
initial treatment regimen before day 0 triggers relapses 
[31]; (ii) blood-stage parasites suppress the develop-
ment of liver-stage parasites [32], and clearance of blood-
stage parasitaemia increases the development rate of 
liver-stage parasites; (iii) short-lived genotype-specific 
immune responses wane during the period of prophylac-
tic protection leading to a rebound in infection rates [33]; 
or (iv) blood-stage parasites originating from relapses are 
suppressed but not cleared by the prophylactic effects of 
AL and CQ, leading to an accumulation of low density 
infections that rebound once drug concentrations wane.
Population‑level parameter estimates
Table  2 presents posterior estimates of the population-
level parameters. In PNG children living in an area with 
hyperendemic P. falciparum transmission, the duration 
of blood-stage infection detectable by molecular geno-
typing was 36 (95% credible interval (CrI): 29, 44) days. 
In Thailand where P. falciparum infection was rare, the 
duration of blood-stage infection was 135 (95% CrI 94, 
191) days. The shape parameter for the distribution of 
the duration of P. falciparum infection in PNG was 0.50 
(95% CrI 0.45, 0.57) < 1, suggesting over-dispersion in 
infection, i.e. many short-lived infections with a small 
number of infections of long duration. In Thailand, the 
estimated shape parameter for P. falciparum was 1.15 
(95% CrI 0.79, 1.78). Notably a shape parameter of 1 cor-
responds to an Exponential distribution for the dura-
tion of infection. The duration of blood-stage P. vivax 
infections was shorter than the duration of blood-stage 
P. falciparum infection in both settings: 24 (95% CrI 21, 
28) days in PNG, and 29 (95% CrI 27, 32) days in Thai-
land. However, these estimates of the duration of blood-
stage P. vivax infection should be interpreted in light of 
the results from the model validation on simulated data, 
where it was found that this parameter was not always 
identifiable. In PNG, which had intense levels of P. vivax 
transmission the average duration of liver-stage infection 
was 383 (95% CrI 313, 467) days. In Thailand, where P. 
vivax transmission was low, the estimate of the duration 
of liver-stage infection did not differ significantly from 
the prior distribution for this parameter (Table 2).
Proportion of P. vivax infections attributable to relapses
There are at least two perspectives on how the propor-
tion of recurrent P. vivax infections attributable to 
relapses can be estimated. Firstly, the probability that 
an individual’s next infection is a relapse can be consid-
ered. Secondly, the proportion of total infections that 
are due to relapses can be considered (possibly including 
repeated acquisition of the same genotype due to multi-
ple relapses). If no liver-stage hypnozoites are present in 
an individual, the next infection must be a primary infec-
tion from a mosquito bite. An infectious mosquito bite 
Fig. 6 Predicted prevalence of the 14 most common P. falciparum and P. vivax genotypes in a, b the PNG placebo arm; c, d the PNG primaquine 
arm; and e, f Thailand. For both P. falciparum and P. vivax each genotype is represented by a different colour. The period of prophylactic protection in 
PNG is shown in grey
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will be followed by a period of blood-stage parasitaemia. 
During this period, relapses of the same genotype may 
occur (i.e. hypnozoites activate), however this event will 
be impossible to detect as it is not possible distinguish 
between clonal blood-stage parasites from primary infec-
tion or relapses using currently available methods. Fur-
thermore, as the activation of hypnozoites is likely to be 
highest immediately after primary infection [6] when 
infected individuals are also likely to have the greatest 
number of hypnozoites, the proportion of relapses hid-
den by blood-stage parasitaemia from the primary infec-
tion may be quite substantial. As many relapses are likely 
to be undetectable, the estimated proportion of total 
infections that are due to relapses will be higher than the 
probability that a recurrent blood-stage infection is initi-
ated by a relapse.
For a new P. vivax infection of a given genotype in 
an individual, the probability that it was initiated by 
a relapse can be estimated (Fig.  4). Figure  7 shows how 
these probabilities can be aggregated across all individu-
als to provide estimates of the proportion of infections 
due to relapses of each genotype on the population-level 
(solid lines). When the ratio of relapses to total infections 
is estimated (dashed lines in Fig. 7), relapses constituted 
76–90% of total infections in the placebo arm of the PNG 
cohort, and 79% in the Thai cohort. In the primaquine 
arm of the PNG cohort, the proportion of relapses is 
predicted to be zero immediately after clearance of liver-
stage hypnozoites, increasing over the course of the study 
to the same levels as observed in the placebo arm. Nota-
bly, for more common genotypes, a lower proportion 
of infections is expected to be attributable to relapses, 
because re-infection with the same genotype is more 
likely.
Discussion
The statistical model presented here allows infection 
dynamics to be investigated on both an individual and 
a population-level. Data from two populations with 
different study designs were analysed: (i) a treatment-
reinfection study in Papua New Guinean children, with 
and without clearance of liver-stage hypnozoites by pri-
maquine; and (ii) a longitudinal observational cohort 
study in Thai participants of all ages. The average dura-
tion of P. vivax blood-stage infection in PNG was esti-
mated as 24 (95% CrI 21, 28) days, slightly shorter than 
in Thailand (29 (95% CrI 27, 32) days), which had lower 
levels of P. vivax transmission. In PNG, which had mod-
erate levels of P. falciparum transmission, the aver-
age duration of P. falciparum blood-stage infection was 
36 (95% CrI 29, 44) days, substantially shorter than has 
been reported in some African populations in higher 
transmission settings, where it has been estimated to be 
70–179  days [34]. In Thailand where infection with P. 
falciparum was rare, the average duration of blood-stage 
infection was 135 (95% CrI 94, 191) days. The variation in 
the estimated duration of blood-stage infection between 
different populations may be due to differences in levels 
of naturally-acquired immunity, population genetic dif-
ferences in host response to infection, variation in strains 
selected for differing local environments, or the choice of 
analysis method.
When the performance of the model was assessed 
against simulated P. falciparum data, it was able to 
Fig. 7 Population-level proportion of P. vivax relapses in a the PNG placebo arm; b the PNG primaquine arm; and c Thailand. Solid lines show 
the proportion of new P. vivax infections due to relapses, and dashed lines show the proportion of total P. vivax infections due to relapses. The 
coloured lines depict the result for each genotype and the black lines show the average across all genotypes. The difference between the solid 
and dashed lines is due to relapses that are undetectable because they occur when blood-stage parasites of the same genotype are already 
circulating. If an individual has not been recently exposed, then their next P. vivax infection is more likely to be from a mosquito bite. For example, 
in low transmission Thailand, if an individual has had no detectable blood-stage infection for > 9 months, the probability that a new infection is due 
to a relapse is low, as liver-stage infection of this duration without relapsing is unlikely. However, once a new infection does occur, it is likely to be 
followed by multiple relapses hence the high proportion of total infections due to relapses
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reliably estimate the population-level parameters (dura-
tion of blood-stage infection and detectability) across 
a wide range of parameter space. However, assessment 
of the statistical methods on simulated P. vivax data 
sets reveals a substantial limitation, that the duration 
of blood-stage P. vivax infection and the time to next 
relapse cannot be reliably estimated. This arises from a 
lack of identifiability between long blood-stage infec-
tions of a single-locus genotype and a short blood-stage 
infection rapidly followed by relapses of the same geno-
type. When a cohort was simulated assuming a long 
duration of blood-stage P. vivax infection, the duration of 
blood-stage infection was substantially underestimated. 
For example, for a blood-stage infection lasting 90 days, 
the method assigns a higher likelihood that it is instead 
a short infection of duration 30  days, rapidly followed 
by two relapses each causing blood-stage infections of 
duration 30  days. This inability to consistently identify 
the parameters for the dynamics of P. vivax infections 
is a major limitation of the method described here. It is 
possible that the model is mis-specified when applied to 
single-locus micro-satellite data with imperfect heterozy-
gosity [19, 27]. This issue may be resolved by an update 
of the model to account for the genetic relatedness in an 
inoculum of sporozoites and the resulting relatedness 
between parasites from a primary infection and relapse 
[35], applied to genotyping data from more sophisticated 
technologies such as familial panels of microsatellites, 
amplicon sequencing, or genome-wide SNP panels [36, 
37].
Despite the inability of the method to accurately esti-
mate the duration of blood-stage P. vivax infection, the 
range of the estimates (24–29  days) can be considered 
consistent with the high proportion of individuals where 
no more than one consecutive sample was observed 
(Fig.  1). An alternative approach is to fit the model for 
P. falciparum infection dynamics to the P. vivax data. 
Although, this model does not account for relapses, esti-
mates of the duration of blood-stage infection remain 
similarly short: 19 (95% CrI 16, 23) days in PNG and 34 
(95% CrI 31, 39) days in Thailand. In contrast, data from 
malaria-therapy studies indicate that in non-immune 
adults blood-stage infections can persist for 60–70 days, 
and possibly even longer at sub-microscopic densities [4, 
14]. Based on these observations, it is hypothesized that 
a primary P. vivax blood-stage infection may have a long 
duration (especially in malaria-naïve individuals), with 
relapses having a substantially shorter duration of infec-
tion. This concurs with other data from malaria-therapy 
studies demonstrating a reduction in parasite density 
between primary P. vivax infection and secondary infec-
tion with a homologous strain [14]. In individuals in the 
PNG and Thai cohorts with naturally-acquired immunity 
against P. vivax parasites, it is likely that the duration of 
the primary blood-stage infection is also reduced. Fur-
ther evidence can be obtained from observations of 
Plasmodium cynomolgi: a simian malaria parasite that 
is genetically closely related to P. vivax, with many bio-
logical similarities most notably the presence of relapses. 
In controlled infections in rhesus macaques, untreated 
blood-stage infections due to P. cynomolgi had consider-
ably shorter duration (approximately 10  days) than pri-
mary infection [38].
Addressing the knowledge gap on the duration of 
blood-stage P. vivax infections could have substantial 
clinical and public health value. The effectiveness of drug 
treatment strategies for reducing malaria transmission 
will depend on the duration of blood-stage infection: if 
the duration of infection is unknown, then the number 
of transmission events of gametocytes from humans to 
mosquitoes prevented by treatment can’t be assessed [39, 
40]. If blood-stage P. vivax parasitaemia is sustained by 
multiple short infections, then clearing a single infection 
with a blood-stage drug such as artemisinin combination 
therapy (ACT) will cause very little reduction in trans-
mission. In contrast, if the majority of P. vivax infections 
have longer duration expected, increased ACT treatment 
can be seen causing a reduction in transmission, similar 
to what has been seen for P. falciparum [41].
Another substantial limitation concerns the use of 
single-locus genotype markers. A single infectious mos-
quito bite may inoculate batches of parasites with differ-
ent genotypes that may be unrelated or meiotic siblings 
that differ at the locus of interest [35, 37]. Furthermore, 
unrelated parasites may have the same genotype at the 
locus considered, although the expected heterozygosity 
of the genotyping markers is > 90%. It is also possible that 
a relapse may have a different genotype to its primary 
infection, but still be a half-sibling. To overcome these 
challenges, multiple-locus genotype markers are being 
developed, which should provide an even richer pat-
tern of P. falciparum and P. vivax infection dynamics. In 
particular, the utilization of multi-locus genotype mark-
ers may resolve the issue of identifiability faced here by 
allowing a relapse to be distinguished from a primary 
blood-stage infection in cases where they are meiotic 
siblings.
There are a number of other limitations to the ana-
lytic methods applied here. Firstly, the role of heteroge-
neity and seasonality in exposure to mosquito bites are 
not accounted for, which is likely to increase the preva-
lence of co-infection with multiple P. falciparum and P. 
vivax genotypes. However, application of the methods 
to simulated data assuming heterogeneity or seasonal-
ity in exposure suggested that population-level param-
eters can still be estimated. Secondly, it is assumed that 
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during co-infection, infections of different genotypes 
(both within and between species) are independent 
of one another. However it is likely that they interact 
due to induced innate immune responses and den-
sity-dependent regulation [42]. Thirdly, it is assumed 
relapses have a tropical phenotype [7, 8] and occur at 
a constant rate following primary infection, thus the 
authors do not account for the variation in relapse rate 
that may arise due to variation in the number of hypno-
zoites in the liver [29]. In particular, it is assumed that 
time to next relapse is exponentially distributed when 
the data may be better described by a more flexible dis-
tribution such as a Weibull distribution [17].
The predicted results may also depend on the fre-
quency of sampling. To investigate this, alternate sam-
ples from individuals in the PNG cohort were excluded, 
and after repeating the analysis found only limited dif-
ferences in the estimated population-level parameters 
(see Additional file  4: Fig. S4.2). The results may also 
depend on genotype detectability. Prior information 
from a series of experiments was relied upon where 
two blood samples were taken 24 h apart and the pres-
ence of genotypes compared between the two samples 
[43]. Higher parasite densities were found to increase 
genotype detectability, and increased multiplicity of 
infection (MOI) was found to reduce detectability. In 
addition, data from malaria-therapy studies has dem-
onstrated a reduction in parasite density between pri-
mary P. vivax infection and secondary infection with 
a homologous strain [14]. Therefore, the assumption 
of constant genotype detectability may be a limitation 
of the method, leading to underestimation of the pro-
portion of P. vivax relapses which may go undetected 
because of their lower blood-stage parasite densities. 
Finally, 100% specificity of genotype detection is also 
assumed. Imperfect specificity and density-dependent 
sensitivity will be investigated in future work.
Despite increasingly detailed observations of hypno-
zoites in  vivo [44], the biological processes regulating 
hypnozoite activation remain unknown [9]. The com-
bination of longitudinal data collection, genotyping 
of samples, and statistical modelling presented here 
provides a new approach for investigation of P. vivax 
recurrences. Whilst recurrences cannot be definitively 
classified into re-infections, recrudescences or relapses, 
the probability of each can be estimated, allowing a 
probabilistic relapse phenotype to be assigned to a P. 
vivax positive sample and, therefore, investigate the 
statistical association between relapses and epidemio-
logical covariates.
The association between anti-malarial treatment and 
the incidence of P. vivax relapses in a population is 
complex, and depends on the duration of prophylactic 
protection provided by the drug [27]. After the initial 
treatment regimen of AL plus CQ in the placebo arm of 
the PNG cohort, a rebound in P. vivax genotype preva-
lence is observed (Fig.  6b). Similar findings have been 
reported by Tarning et  al. [45], where a surge in the 
incidence of P. vivax relapses is predicted at 3, 6 and 
9  weeks following treatment with dihydroartemisinin-
piperaquine. It is hypothesized that this is due to the 
suppression by treatment prophylaxis of blood-stage 
parasites originating from relapses, with parasite densi-
ties rebounding after drug concentrations have waned.
The statistical model presented here provides a use-
ful tool for detailed analysis of P. falciparum and P. 
vivax infection dynamics in longitudinal cohort stud-
ies. There are potentially important contributions to 
be made in the study of P. vivax, where infections can 
be assigned a probabilistic relapse phenotype allowing 
investigation of the association between epidemiologi-
cal covariates and the incidence of relapses, facilitating 
a better understanding of the contribution of relapses 
to P. vivax transmission.
Conclusion
The dynamics of P. vivax infections remain poorly 
understood, with no reliable estimates of the duration 
of blood-stage infection in populations in endemic 
areas with naturally-acquired immunity. P. vivax and 
P. falciparum infection dynamics can be investigated 
by analysing single-locus genotyping data from partici-
pants in longitudinal studies in malaria-endemic areas. 
A mathematical model where the times of infection and 
clearance of blood-stage parasites allows for the infec-
tion dynamics of P. falciparum to be estimated. How-
ever, such a model was not able to reliably estimate 
the parameters describing the infection dynamics of 
P. vivax. It is anticipated that further development of 
these methods and application to more informative 
genotyping markers will allow for a deeper understand-
ing of P. vivax infection dynamics.
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